1.14.99.29 1,10-Diaminodecane 94% of initial activity at 2 mM 7963 1.14.99.29 1,10-phenanthroline complete inhibition at 0.01 mM 62 1.14.99.29 1,3-diaminopropane 86% of initial activity at 0.5 mM 721 1.14.99.29 1,6-diaminohexane 97% of initial activity at 2 mM 1524 1.14.99.29 1,7-Diaminoheptane 91% of initial activity at 2 mM 1960 1.14.99.29 1,8-diaminooctane 93% of initial activity at 2 mM 2927 1.14.99.29 2,2'-dipyridyl - 375 1.14.99.29 2,2'-dipyridyl IC50 0.026 mM 375 1.14.99.29 2,2'-dipyridyl IC50 0.029 mM 375 1.14.99.29 2,2'-dipyridyl targets the active metalloenzyme and inhibits DOHH in human vascular endothelial cells 375 1.14.99.29 2,3-Dihydroxybenzoic acid slight inhibition at 2 mM 3773 1.14.99.29 2-(2-hydroxy-5-methylphenyl)-1,3-thiazole-4-carboxylic acid inhibition in vitro and in cells 108018 1.14.99.29 2-(2-hydroxy-5-methylphenyl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid inhibition in vitro and in cells 49694 1.14.99.29 2-(4-methoxyphenyl)-6-[[2-(4-methoxyphenyl)-3H-benzimidazol-5-yl]methyl]-1H-benzimidazole 94.1% inhibition at 0.002 mM 222524 1.14.99.29 3,4-dihydroxybenzoic acid above 50% inhibition at 2 mM 1781 1.14.99.29 4,6-diphenyl-1-hydroxy-pyridine-2-one IC50 0.0007 mM 49795 1.14.99.29 alkyl 4-oxo-piperidine 3 carboxylates structurally related to dihydropyrimidines, most potent, putative DOHH inhibitors in vitro 165842 1.14.99.29 CaCl2 98% of initial activity at 0.005 mM 218 1.14.99.29 cadaverine 87% of initial activity at 0.5 mM 533 1.14.99.29 caldine 47% of initial activity at 0.5 mM 21554 1.14.99.29 ciclopirox IC50 0.005 mM, complete inhibition above 0.01 mM 13273 1.14.99.29 ciclopirox IC50 0.0006 mM 13273 1.14.99.29 ciclopirox CPX, topical fungicide 13273 1.14.99.29 ciclopirox targets the active metalloenzyme and inhibits DOHH in human vascular endothelial cells 13273 1.14.99.29 ciclopirox - 13273 1.14.99.29 Co(C2H3O2)2 94% of initial activity at 0.005 mM 49951 1.14.99.29 Co(C2H3O2)2 above 0.01 mM 49951 1.14.99.29 CuCl2 above 0.01 mM 347 1.14.99.29 deferiprone IC50 0.117 mM 5318 1.14.99.29 deferiprone 0.2 mM in cells 5318 1.14.99.29 deferiprone DEF, systemic medicinal iron chelator 5318 1.14.99.29 deferiprone targets the active metalloenzyme and inhibits DOHH in human vascular endothelial cells 5318 1.14.99.29 deferiprone - 5318 1.14.99.29 deferoxamine targets the active metalloenzyme and inhibits DOHH in human vascular endothelial cells 23293 1.14.99.29 desferrioxamine B IC50 0.016 mM 49980 1.14.99.29 desferrioxamine mesylate - 21298 1.14.99.29 EDTA high ionic strength EDTA, Tris concentrations above 30 mM 21 1.14.99.29 EDTA - 21 1.14.99.29 EDTA IC50 0.0003 mM 21 1.14.99.29 ethyl 3,4-dihydroxybenzoate IC50 0.5 mM 32633 1.14.99.29 FeCl3 65% of initial activity at 0.005 mM 702 1.14.99.29 FeSO4 13% of initial activity at 0.005 mM 655 1.14.99.29 iron chelators - 12928 1.14.99.29 Lys-Thr-Gly-deoxyhypusine-His-Gly-His-Ala-Lys competitive inhibition 50085 1.14.99.29 methyl 2,3-dihydroxybenzoate IC50 1.6 mM 50099 1.14.99.29 metipirox IC50 0.0028 mM 50106 1.14.99.29 mimosine IC50 0.191 mM 4892 1.14.99.29 mimosine reversible inhibition 4892 1.14.99.29 mimosine S-isomer, complete inhibition at 0.2 mM in LAZ463 cells 4892 1.14.99.29 mimosine IC50 0.0033 mM 4892 1.14.99.29 mimosine 0.2 mM in cells 4892 1.14.99.29 mimosine inhibition of enzyme resulting in reduction of steady-state level of transcription initiation factor eIF5A. Effect does not appear to be involved in the modulation of differentiation-related gene 1 expression by mimosine 4892 1.14.99.29 mimosine targets the active metalloenzyme and inhibits DOHH in human vascular endothelial cells 4892 1.14.99.29 mimosine inhibits progression of cells from the G1 to S-phase by DOHH inhibition. DOHH reactivation occurs rapidly after inhibitor withdrawal and correlates with synchronized entry into the S-phase. Toxic in vivo 4892 1.14.99.29 mimosine synergistic growth inhibition with the combination of miR-331-3p and miR-642-5p and mimosine 4892 1.14.99.29 Mn(C2H3O2)2 above 0.001 mM 109178 1.14.99.29 MnCl2 64% of initial activity at 0.005 mM 307 1.14.99.29 additional information no inhibition by CuSO4, HgCl2, MgCl2, CdSO4 at 0.005 mM; partial reconstitution of 0.01 mM 1,10-phenanthroline inhibited activity with Co(C2H3O2)2 at 0.03 mM or FeSO4 at 0.005 mM 2 1.14.99.29 additional information no inhibition by 2-oxoglutarate, 2-oxoadipinate, 2-oxosuccinate, 3-oxoglutarate, glutarate, malonate, pyruvate 2 1.14.99.29 additional information no inhibition by S-isomers of kojic acid, 3-pyridylalanine, 4-pyridylalanine at 0.3 mM in vitro and at 0.2 mM in cells, no inhibition by 2-(2-aminophenyl)-1,3-thiazole-4-carboxylic acid at 0.4 mM in cells 2 1.14.99.29 additional information partial reconstitution of chelator inhibited activity with CuCl2 or Zn(C2H3O2)2 2 1.14.99.29 additional information no inhibition at 2 mM N-(2-cyanopropyl)-3-cyanopropylamine 2 1.14.99.29 additional information partial reconstitution of 0.01 mM 1,10-phenanthroline inhibited activity with Co(C2H3O2)2 at 0.03 mM or FeSO4 at 0.005 mM 2 1.14.99.29 additional information a number of metal-chelating inhibitors of DOHH causes growth inhibition and G1 cell cycle arrest in mammalian cells 2 1.14.99.29 additional information design of inhibitors against the human parasite enzyme from Plasmodium falciparum might profit from structural differences and the five HEAT-like repeats present in the parasite DOHH that differ in number and amino acid identity from its human orthologue, which contains four repeats 2 1.14.99.29 additional information design of inhibitors against the parasite enzyme might profit from structural differences and the five HEAT-like repeats present in the parasite DOHH that differ in number and amino acid identity from its human orthologue, which contains four repeats. Compounds related structurally to dihydropyrimidines, like the plant amino acid mimosine and the antifungal drug ciclopiroxolamine, are toxic and/or not effective in vivo as anti-malarial drugs in rodents 2 1.14.99.29 additional information the active site is blocked by two catecholpeptides containing alpha 3,4-dihydroxybenzoyl- and alpha 2,3-dihydroxybenzoyl moiety. The 3,4-dihydroxybenzoyl-containing compound is more potent with a Ki of 32 mM 2 1.14.99.29 N''-guanyl-1,7-diaminoheptane competitive inhibition 212951 1.14.99.29 N-(2-cyanoethyl)butane-1,4-diamine 80% of initial activity at 2 mM 109214 1.14.99.29 N-(3-cyanopropyl)propane-1,3-diamine 79% of initial activity at 2 mM 109216 1.14.99.29 N-phenyl-1-[1-(phenylmethyl)benzimidazol-2-yl]diazenylnaphthalen-2-amine 87.6% inhibition at 0.002 mM 222523 1.14.99.29 N-[4-(3,4-diethoxyphenyl)-1,2,5-oxadiazole-3-yl]-3-methylbenzamide 92.6% inhibition at 0.002 mM 222525 1.14.99.29 N1-acetyl-L-Orn-L-Pro-Gly above 2 mM 109289 1.14.99.29 N1-acetyl-N4-(2,3-dihydroxybenzoyl)-L-Orn-L-Pro-Gly IC50 0.2 mM 50140 1.14.99.29 N1-acetyl-N4-(3,4-dihydroxybenzoyl)-L-Orn-L-Pro-Gly IC50 0.03 mM 32697 1.14.99.29 Ni(C2H3O2)2 above 0.001 mM 109320 1.14.99.29 NiSO4 72% of initial activity at 0.005 mM 2860 1.14.99.29 Picolinic acid - 4859 1.14.99.29 putrescine 85% of initial activity at 0.5 mM 155 1.14.99.29 pyridine 2,3-dicarboxylate - 10764 1.14.99.29 pyridine 2,3-dicarboxylate inhibitory effect of pyridine depends on the carboxyl group position 10764 1.14.99.29 Pyridine 2,4-dicarboxylate - 1592 1.14.99.29 Pyridine 2,4-dicarboxylate inhibitory effect of pyridine depends on the carboxyl group position 1592 1.14.99.29 Pyridine 2,5-dicarboxylate - 3361 1.14.99.29 Pyridine 2,5-dicarboxylate inhibitory effect of pyridine depends on the carboxyl group position 3361 1.14.99.29 Pyridine 3,4-dicarboxylate - 12675 1.14.99.29 Pyridine 3,4-dicarboxylate inhibitory effect of pyridine depends on the carboxyl group position 12675 1.14.99.29 Pyridine 3,5-dicarboxylate - 20490 1.14.99.29 Pyridine 3,5-dicarboxylate inhibitory effect of pyridine depends on the carboxyl group position 20490 1.14.99.29 spermidine 58% of initial activity at 0.5 mM 148 1.14.99.29 spermine 41% of initial activity at 0.5 mM 197 1.14.99.29 thermine 35% of initial activity at 0.5 mM 44874 1.14.99.29 zileuton - 3136 1.14.99.29 zileuton i.e. N-[1-(1-benzothien-2-yl)ethyl]-N-hydroxyurea 3136 1.14.99.29 Zn(C2H3O2)2 above 0.01 mM 109714 1.14.99.29 ZnCl2 93% of initial activity at 0.005 mM 271